Journal of Oncology

Research Article

Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection

Table 3

Independent prognostic factors for OS.
CharacteristicsHeadBody/Tail
Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis
HR95%CIHR95%HR95%CIHR95%CI
Age≤60 yearsReference 0.126  NIReference 0.544  NI
>60 years1.3880.912–2.111    1.3360.524–3.409    
GenderFemaleReference 0.271  NIReference 0.303  NI
Male0.7900.519–1.202    1.6700.630–4.428    
WBC≤10Reference 0.001Reference 0.066Reference 0.648  NI
>102.7621.553–4.909 0.4000.151–1.061 0.0460.000–1.864    
NLR≤3.32Reference 0.280  NIReference 0.941  NI
>3.321.2620.827–1.925    0.9450.210–4.241    
dNLR≤3.32Reference 0.457  NIReference 0.326  NI
>3.321.1930.749–1.900    0.6300.250–1.586    
PLR≤98.13Reference 0.274  NIReference 0.944  NI
>98.131.6570.671–4.092    1.0340.409–2.613    
PNI0Reference 0.588  NIReference 0.237  NI
11.1470.699–1.881    3.3940.449–25.680    
SII≤1000Reference 0.838  NIReference 0.367  NI
>10001.0470.677–1.618    0.0410.000–43.052    
mGPS0Reference    NIReference    NI
10.9640.524–1.7750.907   0.5790.071–4.7390.610   
21.3530.681–2.6850.338   1.1870.118–11.9740.884   
PI0Reference  Reference 0.564Reference    NI
10.3930.204–0.7580.0051.5400.355–6.684 1.8410.734–3.1230.950   
20.4600.229–0.9260.0300.9570.239–3.8260.9511.4520.665–2.2130.945   
ALB (g/L)≤35Reference 0.838  NIReference 0.688  NI
>350.9470.563–1.594    0.6520.081–5.244    
CRP (ng/L)≤3Reference 0.315  NIReference 0.253  NI
>31.2440.813–1.904    1.9640.618–6.243    
CA19-9 (U/ml)≤35Reference 0.019Reference 0.340Reference 0.063  NI
>352.0261.123–3.656 1.3740.715–2.638 4.2640.813–7.831    
CEA (ng/ml)≤5Reference 0.103  NIReference 0.153  NI
>51.4480.928–2.261    1.9510.781–4.873    
HBV infectionAbsenceReference 0.713  NIReference 0.573  NI
Presence1.1860.479–2.935    1.8010.232–13.955    
ChemotherapyNoReference 0.240  NIReference 0.886  NI
Yes0.7760.509–1.185    0.9360.376–2.325    
HemorrhageAbsenceReference 0.954  NIReference 0.402  NI
Presence1.0430.255–4.256    0.0380–80.925    
Pancreatic fistulaAbsenceReference 0.351  NIReference 0.059  NI
Presence1.2480.784–1.986    1.1380.018–1.082    
Biliary fistulaAbsenceReference 0.702  NIReference 0.330  NI
Presence1.1090.652–1.887    0.5270.145–1.914    
Abdominal infectionAbsenceReference 0.143  NIReference 0.887  NI
Presence1.5530.861–2.801    1.1600.151–8.904    
Time period to recurrence (month)>24Reference     Reference  Reference  
≤65.1652.358–11.316<0.00118.3376.998–48.047<0.00110.7411.340–86.0930.02519.4529.010–53.421<0.001
6–124.2121.871–9.4840.00113.9945.341–36.626<0.0017.1930.756–68.4480.0865.3323.761–22.191<0.001
12–243.0721.268–7.4380.0134.8421.814–12.9230.00211.7931.140–12.9980.0381.3911.121–3.3210.011
LN16AbsenceReference LAReference 0.046Reference LAReference 0.908
Presence   2.5061.017–6.172    2.5310.932–4.663 
Tumor differentiationWellReference LAReference  Reference LAReference  
Moderate   2.1311.252–3.6410.006   0.0110.000–0.8710.043
Poor   3.5221.446–5.3120.002   7.0471.123–4.1960.037
Imaging tumor size (cm)≤2Reference LAReference  Reference LAReference  
2–4   0.9150.417–2.0070.824   0.2090.042–2.1240.985
>4   1.0010.492–2.0350.999   0.1800.015–2.1800.178
Local progressionAbsenceReference LAReference <0.001Reference LAReference <0.001
Presence   7.0913.645–13.899    0.0010–0.051 
Liver-only metastasisAbsenceReference LAReference <0.001Reference LAReference 0.001
Presence   11.4905.351–24.397    0.0120.001–0.178 
Lung-only metastasisAbsenceReference LAReference 0.001Reference LAReference 0.287
Presence   4.7801.871–12.351    0.2450.018–3.268 
Local + distant metastasisAbsenceReference LAReference 0.031Reference LAReference 0.917
Presence   4.2141.142–15.550    0.3120.087–3.042 
NI, not included; LA, included in LASSO analysis. Abbreviations as in Table 1.